Brief: Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics
14/05/2024 13:47
May 14 (Reuters) - Enveric Biosciences Inc ENVB.O :
* ENVERIC BIOSCIENCES SIGNS $66.5 MILLION NON-BINDING TERM
SHEET
WITH MINDBIO THERAPEUTICS TO OUT-LICENSE NOVEL PSILOCIN PRODRUG
CANDIDATE FOR MENTAL HEALTH DISORDERS
* ENVERIC BIOSCIENCES INC - MINDBIO WILL SEEK TO ADVANCE A
DRUG
CANDIDATE FROM NPP CLASS FOR NEUROPSYCHIATRIC INDICATIONS SUCH
AS DEPRESSION
Source text for Eikon: ID:nBwbQJkzNa
Further company coverage: ENVB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003